Vasopressin receptor antagonism - a therapeutic option in heart failure and hypertension

Citation
Lm. Burrell et al., Vasopressin receptor antagonism - a therapeutic option in heart failure and hypertension, EXP PHYSIOL, 85, 2000, pp. 259S-265S
Citations number
62
Categorie Soggetti
Physiology
Journal title
EXPERIMENTAL PHYSIOLOGY
ISSN journal
09580670 → ACNP
Volume
85
Year of publication
2000
Pages
259S - 265S
Database
ISI
SICI code
0958-0670(200003)85:<259S:VRA-AT>2.0.ZU;2-S
Abstract
The precise role of vasopressin in the pathophysiology of cardiovascular di sease is controversial, but this peptide hormone is important for several r easons. Firstly, circulating concentrations of vasopressin are elevated in heart failure and some forms of hypertension. Secondly, there is evidence t hat vasopressin is synthesized not only in the hypophysial-pituitary axis b ut also in peripheral tissues including the heart where it acts as a paracr ine hormone. Thirdly, vasopressin has vasoconstrictor, mitogenic, hyperplas tic and renal fluid retaining properties which, by analogy with angiotensin II, may have deleterious effects when present in chronic excess. Finally, the availability of orally active non-peptide vasopressin receptor antagoni sts allows vasopressin receptor antagonism to be considered as a therapeuti c option in cardiovascular disease.